Press Release

Biophytis Announces One Oral and Four Poster Presentations at the Myology 2019 Congress

- **Sarconeos improves respiratory function in animal model of Duchenne Muscular Dystrophy**
- **MYODA clinical design update to evaluate the efficacy of Sarconeos in ambulatory and non-ambulatory boys with Duchenne Muscular Dystrophy**
- **Sarconeos increases muscle function and survival in an animal model of Spinal Muscular Atrophy**

Paris, France, March 27, 2019 - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel treatments for age-related diseases, today announced one oral and four poster presentations at the 6th Annual International Congress of Myology being held from March 25 to 28, 2019 in Bordeaux, France at the Palais des Congrès of Bordeaux-Lac.

The oral presentation titled "BIO101 for DMD – a holistic approach to trial design" will highlight the innovative MYODA clinical design and methodology and will touch upon new approaches to clinical development in rare diseases, including Duchenne Muscular Dystrophy (DMD). The four posters present findings, characterizations, approaches and clinical design of the Company's lead product candidate, Sarconeos (BIO101) for the treatment of DMD and Spinal Muscular Atrophy (SMA).

Stanislas Veillet, Ph.D., chief executive officer of Biophytis said, "The presentation of the *in vivo* effects of Sarconeos (BIO101), our lead drug candidate, including results on respiratory function in mdx mice, a classic model of DMD, supplements previous preclinical data showing positive effects on muscle function and mobility in this animal model and indicates that Sarconeos (BIO101) could potentially be used in the treatment of respiratory function in non-ambulatory boys. We also made significant progress in the preparation of the early phase clinical development of Sarconeos (BIO101) in DMD and are presenting an update of our early phase MYODA clinical program that is now intended to include ambulatory and non-ambulatory boys and incorporates two innovative features: (i) a seamless trial design that allows patients to participate across multiple phases, and (ii) composite clinical endpoints that combine muscle strength, mobility and respiratory function. We are preparing to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) and clinical trial applications to the competent National and/or European regulatory agencies, as soon as possible, with the aim of commencing a clinical trial in 2020, subject to regulatory approval."

"The fourth poster presents our first data in Spinal Muscular Atrophy (SMA). We showed that Sarconeos (BIO101) treatment limited muscle atrophy in a severe SMA-like mouse model. We also observed that Sarconeos (BIO101) treatment increased survival in these mice. These results provide the first evidence that Sarconeos (BIO101) could be an efficient treatment in combination with exon-skipping for SMA patients." continued Dr. Veillet.

Presentation details can be found below:

Plenary Session: Lessons Learned from Negative Trials

Title:	BIO101 for DMD – a holistic approach to trial design
Presenter:	Mounia Chabane
Date/Time:	Wednesday, March 27, 2019 from 9:00-10:30 am / Amphi A

Poster Session: Preclinical Proof of Concept in Duchenne Muscular Dystrophy

Title:	Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy
Authors:	Mathilde Latil, Maria Serova, Sissi On, Blaise Didry-Barca, Stanislas Veillet, René Lafont, Pierre Dilda.
Date/Time:	Wednesday, March 27, 2019 / Pluriel Room
Abstract No.:	P11-116-#351

Poster Session: Clinical Development in Duchenne Muscular Dystrophy

Title:	MYODA clinical program: A new approach unraveling drug effects through a composite outcome score encompassing ambulant to non-ambulant disease stages
Authors:	Mounia Chabane, Waly Dioh, Pierre Dilda, Philippe Dupont, René Lafont, Stanislas Veillet, Thomas Voit, Samuel Agus.
Date/Time:	Wednesday, March 27, 2019 / Pluriel Room
Abstract No.:	P11-128-#459

Title:	The MYODA seamless clinical trial design: a true innovation for rare diseases including DMD
Authors:	Mounia Chabane, Waly Dioh, Pierre Dilda, Philippe Dupont, René Lafont, Stanislas Veillet, Thomas Voit, Samuel Agus.
Date/Time:	Wednesday, March 27, 2019 / Pluriel Room
Abstract No.:	P11-129-#460

Poster Session: Preclinical Proof of Concept in Spinal Muscular Atrophy

Title:	*In vivo* effects of Sarconeos (API BIO101) on mouse model of severe spinal muscular atrophy
Authors:	Cynthia Bézier, Pierre Dilda, René Lafont, Stanislas Veillet, Frédéric Charbonnier, Mathilde Latil, Olivier Biondi.
Date/Time:	Wednesday, March 27, 2019 / Pluriel Room
Abstract No.:	P36-309-#277

About Sarconeos (BIO101)

Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule for the treatment of neuromuscular diseases. Sarconeos (BIO101) is a plant-derived pharmaceutical-grade purification of 20-hydroxyecdysone. Based on cellular and animal studies, we believe it stimulates biological resilience through activation of the MAS receptor, which suggests preservation of muscle strength, function and mobility in various age-related and muscular wasting conditions. Biophytis is currently testing Sarconeos (BIO101) in an ongoing global, randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial (SARA-INT) of 334 patients with sarcopenia, an age-related degeneration of muscle in elderly people leading to mobility disability and ultimately to increased risk of adverse health events and death.

About the MYODA program

Biophytis is preparing to advance an oral pediatric formulation of Sarconeos (BIO101) for Duchenne muscular dystrophy (DMD) into the clinic through its MYODA program, subject to regulatory approval. The MYODA clinical program has been designed to address development challenges in rare diseases and aims to accommodate the needs of DMD patients while maximizing clinical efficiency. It proposes to incorporate two innovative clinical features; (i) a seamless trial design that allows patients to participate across multiple phases, and (ii) composite clinical endpoints that combine muscle strength, mobility and respiratory function and are adapted to the stage of severity of the disease in each patient.

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on the development of novel therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological stresses that lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy. Our second drug candidate, Macuneos (BIO201), is for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit www.biophytis.com.

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are not promises or guarantees and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of the risks and uncertainties that could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please consult the Risk Factors section of the Company's registration document and other regulatory filings filed with the French Autorité des Marchés Financiers (AMF), which are available on the AMF website (www.amf-france.org) and at www.biophytis.com. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

Biophytis Investor Relations Contact
Daniel Schneiderman, CFO
dan.schneiderman@biophytis.com
Tel: +1 (857) 220-9720

U.S. Media Contact
LifeSci Public Relations
Cherilyn Cecchini, M.D.
ccecchini@lifescipublicrelations.com
Tel: +1 (646) 876-5196

Europe Media Contact
Citigate Dewe Rogerson

Antoine Denry
antoine.denry@citigatedewerogerson.com
Tel: +33 (0) 1 53 32 84 78

Source: Biophytis SA